Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302325 · ClinicalTrials.gov registry record
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 20
- Enrollment target
NCT03302325 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 20 participants.
The verdict
NCT03302325 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. 2. To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.
Interventions
- PROCEDURE research blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2020-01-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302325
The ClinicalTrials.gov registry entry for NCT03302325 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which research blood draws is the first listed.
NCT03302325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03302325 about?
NCT03302325 is a clinical study titled "Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC". 1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. 2. To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.
What is the current status of trial NCT03302325?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2017-10-12. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT03302325?
The interventions under investigation include: research blood draws (PROCEDURE).
Who is sponsoring clinical trial NCT03302325?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.